Abstract
BackgroundTyrosine kinase inhibitors (TKIs) have revolutionised the treatment of Chronic Myeloid Leukaemia (CML). Adherence to this chronic treatment is essential to attain the therapeutic objectives expected.PurposeTo identify patients on TKIs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have